FMP
Agile Therapeutics, Inc.
AGRX
NASDAQ
Inactive Equity
Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.
1.51 USD
0.05 (3.31%)
Historical Prices
From:
To:
About
ceo
Mr. Alfred F. Altomari
sector
Healthcare
industry
Drug Manufacturers - Specialty & Generic
exchange
NASDAQ
Description
Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend t...
CIK
0001261249
ISIN
US00847L3087
CUSIP
00847L100
Address
500 College Road East
Phone
609 683 1880
Country
US
Employee
19
IPO Date
May 23, 2014
Financial Statement
Earnings
AGRX Financial Summary
CIK
0001261249
Exchange
NASDAQ
Industry
Drug Manufacturers -...
Sector
Healthcare
CUSIP
00847L100
ISIN
US00847L3087
Country
US
Price
1.51
Beta
1.58
Volume Avg.
143.29k
Market Cap
10.43M
Shares
-
52-Week
0.2-2.63
DCF
0.81
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.89
P/B
-
Website
https://www.agiletherapeutics.com
Upgrades and Downgrades
We are unable to load the data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest AGRX News
GlobeNewsWire
Mar 21, 2024
Correction - Agile Therapeutics to Report Fourth Quarter and...
PRINCETON, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report fourth quarter and full year 2023 financial results before the market opens on Thursday, March 28, 2024.
GlobeNewsWire
Mar 20, 2024
Agile Therapeutics to Report Fourth Quarter and Full Year 20...
PRINCETON, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report fourth quarter and full year 2023 financial results before the market opens on Friday, March 22, 2024.
GlobeNewsWire
Oct 26, 2023
Agile Therapeutics to Report Third Quarter 2023 Financial Re...
Live Conference Call and Webcast at 8:30 a.m. ET PRINCETON, N.J.
The Motley Fool
Sep 28, 2023
Why Shares of Agile Therapeutics Jumped This Week
Agile is seeing strong revenue growth. The company only has one marketed product, a birth control patch.
GlobeNewsWire
Sep 5, 2023
Agile Therapeutics to Present at the H.C. Wainwright 25th An...
PRINCETON, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Chairperson and Chief Executive Officer Al Altomari and Chief Commercial Officer Amy Welsh will present at the H.C. Wainwright 25th Annual Global Investment Conference taking place September 11-13, 2023 in New York, NY.
GlobeNewsWire
Jul 26, 2023
Agile Therapeutics to Report Second Quarter 2023 Financial R...
PRINCETON, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report second quarter 2023 financial results before the market open on Wednesday, August 9, 2023.
Seeking Alpha
May 12, 2023
Agile Therapeutics, Inc. (AGRX) Q1 2023 Earnings Call Transc...
Agile Therapeutics, Inc. (NASDAQ:AGRX ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Matt Riley - Head, Investor Relations Al Altomari - Chairman & Chief Executive Officer Conference Call Participants Oren Livnat - H.C. Wainwright Operator Good day, and thank you for standing by.
GlobeNewsWire
May 8, 2023
Agile Therapeutics to Report First Quarter 2023 Financial Re...
PRINCETON, N.J., May 08, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report first quarter 2023 financial results after the market close on Thursday, May 11, 2023.
